Positron emission tomogrphy in prostate carcinoma
PDF
Cite
Share
Request
Review
P: 46-49
March 2014

Positron emission tomogrphy in prostate carcinoma

Bull Urooncol 2014;13(1):46-49
1. Dokuz Eylu¨L Üniversitesi Tip Faku¨Ltesi, Nu¨Kleer Tip Anabilim Dali, Izmir
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

In this review, the role of positron emission tomography (PET) in prostate cancer will be discussed. Fluorodeoxyglucose (FDG) PET is the most important in determining early staging of disease in patients with aggressive prostatic tumors and for monitoring response to therapy in more advanced patients. Choline PET provide better accuracy than FDG in the detection of local disease, nodal involvement, and distant metastases in prostate cancer but insufficient in low PSA levels. A novel tracer prostate specific membrane antigen (PSMA) can detect prostate cancer relapses and metastases in also low PSA levels.